Ask VialBase
Research

A Study of Retatrutide in Participants With Type 2 Diabetes, Obesity, and Obstructive Sleep Apnea — VialBase Research

Trial Summary

Phase 3 trial evaluating retatrutide in a triple-comorbidity population: T2D + obesity + OSA. This study tests whether the triple-agonist peptide can simultaneously address glycemic control, weight loss, and sleep apnea severity in patients with overlapping metabolic conditions.

Design

  • Type: Randomized, double-blind, placebo-controlled, multicenter
  • Population: Adults with T2D (HbA1c 7-10.5%), BMI 30+, and moderate-to-severe OSA
  • Arms: Retatrutide (multiple doses) vs. placebo
  • Duration: 52-76 weeks
  • Key measures: HbA1c change, AHI change, body weight, CPAP usage, sleep quality, metabolic parameters

Key Outcomes

Active but no longer recruiting; results anticipated. Given Phase 2 data showing ~24% weight loss and robust HbA1c reductions, large AHI improvements are expected.

Significance for Peptide Research

This trial embodies the “one peptide, multiple diseases” thesis for next-generation incretins. Retatrutide’s triple mechanism could simultaneously treat three conditions that currently require separate interventions (metformin/insulin, CPAP, behavioral weight loss). The triple-comorbidity design is pragmatic and reflects real-world patient phenotypes. Success would strengthen the case for multi-agonist peptides as polypharmacy replacements.

See Also